Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14501 - 14525 of 15156 in total
GDC-0349 has been used in trials studying the treatment of Non-Hodgkin's Lymphoma, Solid Tumor.
Investigational
Experimental
Experimental
Verucerfont has been used in trials studying the treatment of Congenital Adrenal Hyperplasia.
Investigational
Cenerimod has been used in trials studying the treatment of Systemic Lupus Erythematosus.
Investigational
Experimental
Trelagliptin is under investigation in clinical trial NCT03555591 (Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus").
Investigational
CTS-21166 is a small-molecule beta-secretase inhibitor, which is being developed as a disease-modifying treatment for Alzheimer's disease. CTS-21166 is the only BACE1 inhibitor that has passed Phase I clinical trial thus far. In 2008, CoMentis revealed this small compound as a transition-state analog inhibitor (structure is currently undisclosed) with excellent...
Investigational
Matched Description: … currently undisclosed) with excellent properties in brain penetration, selectivity, metabolic stability, and
Experimental
Experimental
Displaying drugs 14501 - 14525 of 15156 in total